(Total Views: 465)
Posted On: 11/28/2018 2:29:44 PM
Post# of 30015
![](/m/assets/46931549/no_avatar_available_thumb.jpg)
Quote:
Amarantus management has outlined two distinct paths for Elto Pharma to extract as much value for the Eltoprazine asset for Amarantus as possible: 1) standalone private funding followed by a US or Hong Kong-based IPO, or 2) a business combination with an established clinical-stage biopharmaceutical company with strong management and an exceptional pipeline in which Amarantus could become a significant shareholder. Amarantus expects to make a final determination on the capital formation plan for Elto Pharma in the summer of 2018.
This deal obviously fell through. Because Coeptis is clearly not "an established clinical-stage biopharmaceutical company with strong management and an exceptional pipeline."
Not by any stretch.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)